UBS Group
KRTX

UBS Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

UBS Group’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,400
Closed -$2.66M – 10314
2023
Q4 		$2.66M Sell
8,400
-17,400
-67% -$3.38M ﹤0.01% 3508
2023
Q3 		$4.36M Buy
+25,800
New +$4.85M ﹤0.01% 2704

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

UBS Group's KRTX Position: Q1 2024 in Review

UBS Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 422,178 shares — an estimated $134M sold.

UBS Group first reported a position in KRTX in Q3 2019 and held it in 18 quarters. The position peaked at $134M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • UBS Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • UBS Group sold 422,178 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $134M.
  • UBS Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2019 and held it in 18 quarters.
  • UBS Group's Karuna Therapeutics, Inc. Common Stock position peaked at $134M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.